Hanmi Science Co.,Ltd
Financials
Valuation Metrics
Hanmi Science Co.,Ltd's Market Cap is ₩3.3T. At end of 2025 it was ₩2.5T. Ranked #140 of 2,421 in KR market (top 6%), #122 of 781 on KOSPI (top 16%), #2 of 96 in Health Care Equipment & Services (top 2%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.35T KRW | KR#140/2,421 Sec#2/96 |
| Revenue | 1.41T KRW | KR#330/2,421 Sec#1/96 |
| Net Income | 150.89B KRW | KR#186/2,421 Sec#1/96 |
| Total Assets | 1.53T KRW | KR#369/2,421 Sec#3/96 |
| Net Assets | 1.06T KRW | KR#282/2,421 Sec#2/96 |
| Employees | 453 | KR#542/2,421 Sec#12/96 |
| Value | ||
| P/E | 22.19x | KR#1,213/2,421 Sec#36/96 |
| P/B | 3.16x | KR#2,121/2,421 Sec#77/96 |
| PEG | 0.13x | KR#472/2,421 Sec#22/96 |
| P/S | 2.38x | KR#1,892/2,421 Sec#56/96 |
| EV/EBITDA | 20.22x | KR#1,020/2,421 Sec#34/96 |
| Profitability | ||
| ROE | 14.22% | KR#357/2,421 Sec#11/96 |
| ROA | 9.85% | KR#282/2,421 Sec#14/96 |
| Op. Margin | 12.06% | KR#421/2,421 Sec#25/96 |
| Revenue Growth | 6.30% | KR#1,117/2,421 Sec#63/96 |
| Earnings Growth | 165.36% | KR#281/2,421 Sec#16/96 |
| Financial Health | ||
| Debt Ratio | 44.44% | KR#874/2,421 Sec#48/96 |
| Total Debt | 182.72B KRW | KR#538/2,421 Sec#6/96 |
| Cash | 98.28B KRW | KR#477/2,421 Sec#5/96 |
| Current Ratio | 0.90x | KR#1,834/2,421 Sec#83/96 |
| Net Debt/EBITDA | 0.50x | KR#670/2,421 Sec#27/96 |
| Dividend | ||
| Div. Yield | 0.62% | KR#1,228/2,421 Sec#37/96 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | 21.46% | KR#428/2,421 Sec#9/96 |
| 1M Return | 8.42% | KR#547/2,421 Sec#14/96 |
| From 52W High | -19.75% | KR#253/2,421 Sec#6/96 |
| 1Y MDD | -48.52% | KR#926/2,421 Sec#33/96 |
| Trading | ||
| Volume | 166,878 shares | KR#547/2,421 Sec#20/96 |
| Trading Value | 8.18B KRW | KR#279/2,421 Sec#4/96 |
| Foreign Own. | 1.19% | KR#1,953/2,421 Sec#71/96 |
| Per Share | ||
| EPS | 2,206 KRW | KR#423/2,421 Sec#9/96 |
| BPS | 15,514 KRW | KR#680/2,421 Sec#9/96 |
Company Info
Hanmi Science, established in 1973, received approval for conversion to a holding company in 2011. In 2022, it merged with Hanmi Healthcare, adding a healthcare business division and transforming into an operating holding company. It generates profit through equity gains from subsidiaries, patent and trademark royalty income, healthcare business, and affiliate management, holding 8 subsidiaries including Hanmi Pharmaceutical. As an operating holding company, it is dedicated to discovering new growth engines, sharing new drug development risks, and establishing mid-to-long-term visions to lead the rapidly changing global healthcare market. Hanmi Science is headquartered in Hwaseong-si, Gyeonggi-do.